New Study Reveals Impact of Menthacarin® on Gut Microbiota and SCFA Production
2025-05-12
We are proud to announce the publication of a new scientific article in the renowned journal Frontiers in Pharmacology, highlighting groundbreaking research on Menthacarin®. The study discussed in the article investigates the effects of our active ingredient Menthacarin®, our proprietary formulation of peppermint and caraway oil, on human fecal microbiota composition and SCFA production in an in vitro system.
Key Highlights:
- Menthacarin® significantly alters microbiota composition at both the phylum and genus levels.
- Increases beneficial bacteria such as Firmicutes (+13.6%) and Actinobacteria (+54.9%).
- Decreases harmful bacteria such as Bacteroidetes (−27.7%) and Proteobacteria (−25.7%).
- Enhances production of short-chain fatty acids (SCFAs) including propionate, butyrate, isobutyrate, valerate, and isovalerate.
- Potential therapeutic benefits for gut–brain interaction disorders through normalization of gut dysbiosis.
The study was conducted in collaboration between our R&D team and Acaryon GmbH.
Read the full publication here: